wsbdaily | Tue, 20 Dec 2022 03:11:27 EST Where you find Tomorrow’s Hot Stocks Yesterday!
NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
Pfizer Inc.(PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 trea... Read More
Summary & Charts
| Price | $ 53.61 | -0.87 (-1.6%) |
| Day's Range | $ 53.40 - 54.43 | |
| Previous Close | $ 54.48 | |
| Market Cap | $ 305.81B USD | |
| Short Interest % | N/A | |
| Float | N/A | |
| Outstanding | N/A |
| Exchange | NYSE | |
| Industry | Drug Manufacturers—General | |
| Sector | Healthcare | |
| Volume | 21.55M | |
| Avg. Volume (20 day) | 19.93M | |
| Rel. Volume (20 day) | 1.08 | |
| Rel. Volume (3 month) | 1.03 | |
| Rating | A+ | Buy |
| DCF | N/A | Strong Buy |
| Debt/Equity | 110.61 % | Buy |
| ROE | 35.08 % | Neutral |
| ROA | 17.81 % | Neutral |
| P/E | 10.27 % | Buy |
| P/B | 3.25 % | Strong Buy |
| Date | Open | High | Low | Close | Change | Volume | R. Vol. (20d) | R. Vol. (3m) | Mentions |
|---|---|---|---|---|---|---|---|---|---|
| Dec 15, 2022 | $ 54.07 | $ 54.43 | $ 53.40 | $ 53.61 | -0.87 | 21,551,942 | 1.08 | 1.03 | 1 |
| Dec 14, 2022 | $ 53.14 | $ 54.93 | $ 52.90 | $ 54.48 | +1.41 | 36,261,261 | 1.85 | 1.75 | 3 |
| Dec 13, 2022 | $ 53.10 | $ 54.04 | $ 52.88 | $ 53.07 | +0.91 | 29,462,168 | 1.54 | 1.45 | 4 |
| Dec 12, 2022 | $ 52.12 | $ 52.59 | $ 51.75 | $ 52.16 | +0.44 | 15,493,444 | 0.82 | 0.77 | 1 |
| Dec 09, 2022 | $ 51.75 | $ 52.84 | $ 51.63 | $ 51.72 | -0.06 | 19,934,871 | 1.04 | 0.99 | |
| Dec 08, 2022 | $ 50.18 | $ 51.87 | $ 50.02 | $ 51.78 | +1.54 | 26,117,817 | 1.36 | 1.30 | |
| Dec 07, 2022 | $ 49.75 | $ 51.15 | $ 49.75 | $ 50.24 | +0.53 | 15,931,337 | 0.85 | 0.80 | 1 |
| Dec 06, 2022 | $ 50.66 | $ 50.85 | $ 49.18 | $ 49.71 | -1.02 | 21,789,059 | 1.16 | 1.09 | 2 |
| Dec 05, 2022 | $ 50.91 | $ 51.03 | $ 50.34 | $ 50.73 | -0.18 | 17,959,812 | 0.96 | 0.91 | 3 |
| Dec 02, 2022 | $ 50.56 | $ 51.32 | $ 50.48 | $ 50.91 | -0.17 | 16,882,529 | 0.89 | 0.86 | 10 |
| Dec 01, 2022 | $ 50.31 | $ 51.16 | $ 50.28 | $ 51.08 | +0.95 | 23,592,901 | 1.23 | 1.20 | 4 |
| Nov 30, 2022 | $ 49.64 | $ 50.13 | $ 49.04 | $ 50.13 | +0.64 | 35,575,522 | 1.84 | 1.84 | 1 |
| Nov 29, 2022 | $ 49.50 | $ 49.67 | $ 49.09 | $ 49.49 | -0.08 | 17,162,058 | 0.90 | 0.90 | 1 |
| Nov 28, 2022 | $ 49.18 | $ 49.74 | $ 49.06 | $ 49.57 | +0.36 | 19,410,899 | 0.98 | 1.01 | |
| Nov 25, 2022 | $ 48.93 | $ 49.22 | $ 48.84 | $ 49.21 | +0.36 | 6,760,365 | 0.34 | 0.35 | 1 |
| Nov 23, 2022 | $ 48.96 | $ 49.22 | $ 48.52 | $ 48.85 | -0.23 | 10,711,719 | 0.51 | 0.55 | |
| Nov 22, 2022 | $ 48.34 | $ 49.25 | $ 48.24 | $ 49.08 | +0.90 | 16,358,249 | 0.77 | 0.84 | |
| Nov 21, 2022 | $ 48.10 | $ 48.28 | $ 47.72 | $ 48.18 | -0.05 | 13,746,009 | 0.63 | 0.70 | 1 |
| Nov 18, 2022 | $ 48.64 | $ 48.83 | $ 47.87 | $ 48.23 | -0.10 | 20,666,545 | 0.93 | 1.05 | 1 |
| Nov 17, 2022 | $ 47.80 | $ 48.49 | $ 47.53 | $ 48.33 | +0.28 | 13,238,733 | 0.57 | 0.68 |
News
The latest news about Pfizer Inc. (PFE).
Forbes | 2022-12-16 06:00:00
We believe that Pfizer stock (NYSE: PFE) is currently a better pick than its peer, Johnson & Johnson stock (NYSE: JNJ), given its relatively lower valuation of 3.1x trailing revenues, compared to 4.9x for J&J.
The Motley Fool | 2022-12-16 05:52:00
Pfizer has a lot more revenue at risk over the next several years than AbbVie does.
The Motley Fool | 2022-12-16 05:05:00
Both companies should hurdle their patent cliff concerns.
CNBC | 2022-12-15 19:06:10
Cramer said that healthcare stocks have stayed relatively steady this year because they tend to be recession-resistant stocks.
Fox Business | 2022-12-15 18:00:57
The White House says it was not in any way involved in China's approval of Pfizer's COVID-19 pill to treat an anticipated wave of infections.
Seeking Alpha | 2022-12-14 22:38:04
My top 5 picks for 2022 outperformed the S&P 500 by over 14%. I provide an update for those stocks in this article, two of which remain top picks for the coming year.
Seeking Alpha | 2022-12-12 11:22:35
Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high, longer than expected.
Earnings
| Date | Time | EPS Expected | EPS Reported | % | Revenue Expected | Revenue Reported | % |
|---|---|---|---|---|---|---|---|
| 2022-11-01 | BMO | 1.39 | 1.78 | 28.05% | -- | -- | -- |
| 2022-07-28 | BMO | 1.78 | 2.04 | 14.6% | -- | -- | -- |
| 2022-05-03 | BMO | 1.47 | 1.67 | 13.6% | 22B | 26B | 15.74% |
| 2022-02-08 | BMO | 0.85 | 1.08 | 27.05% | 0.2T | 24B | -89.13% |
| 2021-11-02 | BMO | 1.08 | 1.34 | 24.07% | 22B | 24B | 7.65% |
| 2021-07-28 | BMO | 0.97 | 1.07 | 10.3% | 23B | 19B | -17.04% |
| 2021-05-04 | BMO | 0.77 | 0.93 | 20.77% | 14B | 15B | 7.6% |
| 2021-02-02 | BMO | 0.48 | 0.42 | -12.5% | 6.7B | 5.9B | -11.12% |
Top Discussions
These are the top discussions over the last 24-hours that mention the PFE stock ticker symbol.
Unusual Option Activity
Option contracts that are trading at a significantly higher volume relative to the contract's open interest. These might provide some insight into what "smart money" is doing with large volume orders.
| Type | Strike | Exp Date | DTE | Bid | Ask | Last | Volume | Open Interest | Vol/OI | IV |
|---|---|---|---|---|---|---|---|---|---|---|
| PUT | $ 53.50 | 12/15/22 | 0 | $ 0.28 | $ 0.35 | $ 0.32 | 943 | 643 | 1.47 | 0.36% |
| PUT | $ 54.50 | 12/15/22 | 0 | $ 0.89 | $ 1.06 | $ 0.99 | 201 | 153 | 1.31 | 0.44% |
| PUT | $ 57.50 | 12/15/22 | 0 | $ 3.75 | $ 4.05 | $ 2.57 | 165 | 55 | 3.00 | 0.63% |
| PUT | $ 58.00 | 12/15/22 | 0 | $ 4.25 | $ 4.60 | $ 3.70 | 52 | 13 | 4.00 | 0.84% |
| PUT | $ 48.50 | 12/22/22 | 6 | $ 0.03 | $ 0.05 | $ 0.03 | 113 | 76 | 1.49 | 0.39% |
| PUT | $ 49.00 | 12/22/22 | 6 | $ 0.04 | $ 0.05 | $ 0.05 | 987 | 624 | 1.58 | 0.36% |
| PUT | $ 52.00 | 12/22/22 | 6 | $ 0.22 | $ 0.25 | $ 0.23 | 320 | 150 | 2.13 | 0.26% |
| PUT | $ 42.00 | 01/05/23 | 20 | $ 0.01 | $ 0.03 | $ 0.07 | 220 | 82 | 2.68 | 0.46% |
| PUT | $ 44.00 | 01/05/23 | 20 | $ 0.02 | $ 0.04 | $ 0.11 | 60 | 44 | 1.36 | 0.40% |
| PUT | $ 46.00 | 01/05/23 | 20 | $ 0.01 | $ 0.06 | $ 0.05 | 203 | 79 | 2.57 | 0.35% |
| PUT | $ 54.00 | 01/05/23 | 20 | $ 1.26 | $ 1.41 | $ 1.22 | 439 | 118 | 3.72 | 0.23% |
| PUT | $ 51.00 | 01/12/23 | 27 | $ 0.49 | $ 0.58 | $ 0.55 | 844 | 149 | 5.66 | 0.26% |
| PUT | $ 62.50 | 01/19/23 | 34 | $ 8.80 | $ 9.00 | $ 11.55 | 150 | 111 | 1.35 | 0.30% |
| PUT | $ 70.00 | 01/19/23 | 34 | $ 16.25 | $ 16.55 | $ 19.05 | 158 | 46 | 3.43 | 0.49% |
| CALL | $ 54.00 | 01/26/23 | 41 | $ 1.60 | $ 1.77 | $ 1.79 | 69 | 51 | 1.35 | 0.27% |
| CALL | $ 62.00 | 01/26/23 | 41 | $ 0.08 | $ 0.17 | $ 0.10 | 310 | 141 | 2.20 | 0.29% |
| PUT | $ 52.50 | 03/16/23 | 90 | $ 2.21 | $ 2.30 | $ 2.27 | 1,346 | 1,055 | 1.28 | 0.27% |
| PUT | $ 22.50 | 01/16/25 | 762 | $ 0.45 | $ 0.61 | $ 0.45 | 380 | 226 | 1.68 | 0.41% |
Last Updated: Thu, 15 Dec 2022 22:10 EST
Failures to Deliver
Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.
Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.
Last Updated: Mon, 13 Dec 2021 12:00 EST
@wsbdaily
wsbdaily